Pelthos Therapeutics (PTHS) Q2 2026: Zelsuvmi Units Dispensed Surge 48%, Strengthening Market Leadership
Pelthos Therapeutics demonstrated robust commercial momentum in its lead product Zelsuvmi, with a 48% quarter-over-quarter increase in units dispensed, underscoring growing adoption in the molluscum contagiosum market. The company’s strategic contract with a major pharmacy benefit manager has catalyzed demand, while preparations for complementary product launches remain on track. Investors should monitor the operational leverage potential from upcoming launches and evolving gross-to-net dynamics.
Summary
- Prescription Growth Acceleration: Zelsuvmi's expanding prescriber base and unit demand confirm strong market penetration.
- Commercial Infrastructure Leverage: Upcoming launches of Xepi and Xeglyze poised to capitalize on existing salesforce efficiencies.
- Gross-to-Net Trajectory: Anticipated shift toward mid-30% GTN rates signals evolving pricing and reimbursement dynamics.
Business Overview
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on dermatological infectious diseases, primarily through its portfolio of topical treatments. The company generates revenue mainly from product sales of Zelsuvmi, an FDA-approved at-home treatment for molluscum contagiosum, with planned launches of Xepi for impetigo and Xeglyze for head lice. These products target large, underserved pediatric and dermatology markets, leveraging a specialized commercial infrastructure.
Performance Analysis
During the second quarter of 2026, Pelthos reported $15.4 million in net product revenue from Zelsuvmi, marking a 45% increase from $10.7 million in the prior quarter. This growth was driven by a 48% increase in dispensed units, rising from 8,084 to 11,925, alongside an expanding prescriber base that grew by 39% to 4,571 unique healthcare providers. The increase in prescriptions reflects effective commercial execution and successful contracting with a major pharmacy benefit manager, which boosted units dispensed within that network by 81.3% and prescribers by 68% during the quarter.
Cost of goods sold (COGS) rose to $3.6 million from $1.7 million, influenced by inventory write-offs and fair value adjustments related to the company's acquisition accounting. Selling, general and administrative (SG&A) expenses increased by 31% quarter-over-quarter to $27.7 million, primarily due to $5.3 million in one-time sales milestones and higher royalties, partially offset by reductions in marketing and regulatory expenses. Adjusted EBITDA improved sequentially, narrowing the loss to $5.7 million from $8.0 million, reflecting operational leverage as revenue scales.
- Inventory Management Insight: Minimal increase in wholesale inventory and reduced days on hand indicate efficient supply chain control supporting demand growth.
- Salesforce Expansion: Addition of three new sales territories enhanced market coverage, supporting continued prescription growth.
- Gross-to-Net Trends: GTN rates at 29.6% are expected to rise to mid-30% levels, reflecting evolving payer negotiations and discount structures.
Overall, Pelthos's financial and operational performance in Q2 demonstrates a strong commercial ramp for Zelsuvmi, with foundational investments and cost structures positioning the company for sustainable growth and upcoming product launches.
Executive Commentary
"The growing adoption of Zelsuvmi and an increasing number of prescriptions written contributed significantly to our strong performance in the second quarter. We expect further growth for Zelsuvmi, with over 4,200 units dispensed in July and total units dispensed since the launch surpassing a significant milestone of 30,000. We believe that our continued commercial success, combined with the Horizon facility, and potential access to additional funds subject to the lender’s discretion, will provide us with the capital and flexibility necessary to advance our business plan."
Scott Plesha, Chief Executive Officer
"For the second quarter of 2026, we reported $15.4 million of net product revenue, representing a 45% increase from the first quarter of 2026. Cost of goods sold for the second quarter also included a $0.9 million write-off of commercial API inventory identified through our quality control processes, but we have addressed the underlying procedural cause. Our SG&A increase was primarily due to non-recurring sales milestones and higher royalties, while cash basis SG&A excluding these items remained relatively stable."
John Gay, Chief Financial Officer
Strategic Positioning
1. Robust Commercial Execution Driving Zelsuvmi Growth
Pelthos has effectively expanded its salesforce footprint to 67 territories, including recent additions in Pennsylvania, New York, and Louisiana, enabling broader healthcare provider engagement. The successful contract with a major pharmacy benefit manager has reduced patient access friction, accelerating prescription volume and prescriber adoption. This strategic contracting and targeted sales efforts underpin the strong quarter-over-quarter growth trajectory for Zelsuvmi.
2. Leveraging Synergies for Upcoming Product Launches
The company plans to launch Xepi in Q1 2027 and Xeglyze in Q3 2027, both FDA-approved treatments addressing impetigo and head lice respectively. These products share significant call point overlap with Zelsuvmi, allowing Pelthos to leverage its existing commercial infrastructure and salesforce for efficient market entry. Manufacturing scale-up efforts are underway, with minimal incremental marketing spend anticipated due to operational synergies.
3. Navigating Gross-to-Net Dynamics and Payer Relationships
Pelthos’s gross-to-net (GTN) rate stood at 29.6% in Q2, reflecting discounts, Medicaid rebates, and copay assistance programs. Management expects GTN to increase to the mid-30% range, driven by potential new payer contracts and evolving reimbursement structures. Effective management of GTN will be critical to maintaining healthy margins as sales volumes expand.
4. Financial Strength and Capital Flexibility
The $50 million senior secured term loan facility with Horizon Technology Finance, including an initial $30 million draw and potential access to an additional $10 million, provides Pelthos with a stable capital base to support commercial expansion and pipeline development. The company’s cash position of $24.2 million and working capital of $31.4 million underpin operational runway through upcoming launches.
5. Focused Business Development Approach
Pelthos continues to evaluate additional acquisition opportunities, prioritizing novel, first-in-class assets that complement its current dermatology portfolio. While open to assets beyond its geographic base, the company emphasizes strategic fit over volume, avoiding me-too products to maintain differentiation and market leadership.
Key Considerations
Pelthos’s second quarter results highlight a commercial-stage biopharma effectively scaling a novel dermatology product while preparing for complementary launches. Its focus on operational leverage, payer contracting, and targeted sales expansion are critical to sustaining momentum.
- Prescription Momentum: The 48% increase in Zelsuvmi units dispensed reflects strong market acceptance and effective sales execution.
- Inventory Efficiency: Minimal channel inventory build and reduced days on hand suggest disciplined supply chain management supporting demand.
- Gross-to-Net Evolution: Rising GTN rates will require careful management to protect margins amid growth.
- Upcoming Launch Synergies: Xepi and Xeglyze launches will test the scalability of Pelthos’s commercial infrastructure and financial discipline.
- Capital Deployment: Horizon facility availability and cash position provide flexibility but require disciplined execution to extend runway.
Risks
Pelthos faces risks including potential volatility in gross-to-net rates, manufacturing challenges for upcoming launches, and competitive dynamics within dermatology. The company’s reliance on payer contracting to expand access and reimbursement introduces uncertainty. Additionally, the seasonal nature of molluscum contagiosum treatment demand and the acute care setting may cause prescription volatility.
Forward Outlook
For the third quarter of 2026, Pelthos anticipates stable to modestly increasing prescription volumes for Zelsuvmi, with early signals indicating a stable claims environment despite typical seasonal variations. Gross-to-net rates are expected to move toward the mid-30% range as new payer contracts are negotiated. The company is progressing manufacturing scale-up and regulatory preparations for the planned launches of Xepi in Q1 2027 and Xeglyze in Q3 2027. No formal revenue or earnings guidance was provided due to the early stage of launch.
Takeaways
Pelthos Therapeutics is demonstrating tangible commercial progress with its lead product Zelsuvmi, capitalizing on first-mover advantage in an underserved pediatric dermatology segment. The company’s strategic contracting and salesforce expansion have driven significant prescription growth, while prudent inventory and cost management have maintained operational discipline.
- Commercial Growth Validated: The 48% quarter-over-quarter increase in units dispensed and expanding prescriber network signal robust market adoption and effective sales execution.
- Operational Leverage Ahead: Upcoming launches of Xepi and Xeglyze will leverage existing infrastructure, offering potential margin expansion and portfolio diversification.
- Margin Management Critical: Rising gross-to-net rates and manufacturing scale-up costs will require vigilant financial oversight to sustain profitability as the business scales.
Conclusion
Pelthos’s Q2 2026 results underscore a successful commercial ramp for Zelsuvmi, supported by effective contracting and sales expansion. The company is well positioned to extend its dermatology portfolio with complementary product launches, leveraging operational synergies to drive sustainable growth. Investors should watch gross-to-net trends and launch execution as key determinants of future financial performance.
Industry Read-Through
Pelthos’s experience highlights the importance of strategic payer contracting and commercial infrastructure scale in specialty dermatology markets, particularly for novel at-home treatments. The ability to integrate complementary products into existing sales channels can drive operational leverage and margin improvement. Additionally, managing gross-to-net dynamics remains a critical challenge for biopharma companies launching specialty therapies in competitive, insurance-driven environments. Other companies in the dermatology and pediatric infectious disease sectors should monitor Pelthos’s approach to contracting, inventory management, and portfolio expansion as a potential blueprint for sustainable commercial growth.